Nobuhisa Hagiwara    Department   Other, Other    Position
Article types	Original article
Language	English
Peer review	Peer reviewed
Title	Effectiveness and safety of dabigatran versus warfarin in real-world Japanese patients with atrial fibrillation: A single-center observational study
Journal	Formal name：Journal of Arrhythmia Abbreviation：J Arrhythmia ISSN code：1880-4276/1883-2148
Domestic / Foregin	Domestic
Publisher	Japanese Heart Rhythm Society
Volume, Issue, Page	33(2),pp.107-110
Author and coauthor	NAGANUMA Miyoko†, SHIGA Tsuyoshi*, NAGAO Takehiko, SUZUKI Atsushi, MURASAKI Kagari, HAGIWARA Nobuhisa
Authorship	Last author
Publication date	2017/04
Summary	BACKGROUND: In "real-world" practice, anticoagulant therapy is indicated for patients whose clinical profiles are not addressed in randomized clinical trials. We assessed the effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with non-valvular atrial fibrillation (NVAF). METHODS: Among 613 NVAF patients who initiated dabigatran or warfarin therapy during the period between 2011 and 2013, 362 patients were included in the study after propensity score adjustment. The median follow-up period was 1.3 years. The effectiveness and safety outcomes were thromboembolism and major bleeding, respectively. RESULTS: The propensity-matched hazard ratios of thromboembolism and major bleeding with dabigatran were 1.03 (95% CI: 0.12-8.04, p=0.971) and 0.15 (95% CI: 0.01-0.90, p=0.037), respectively. CONCLUSIONS: The ability of dabigatran to prevent thromboembolism is comparable to that of warfarin; however, the major bleeding rate is lower with dabigatran in "real-world" NVAF patients.
DOI	http://dx.doi.org/10.1016/j.joa.2016.07.007
PMID	28416975